OM-89 Activates Bladder Cell Lysosomes to Clear Intracellular E. coli and Raise Antibiotic Levels

Researchers exposed differentiated bladder epithelial cultures and organoids to OM-89, then infected them with clinical E. coli strains before adding antibiotics. OM-89 raised LAMP1-positive lysosomes, acidified compartments, and lysosomal enzyme activity; blocking acidification abolished the effect. The same treatment doubled intracellular antibiotic concentrations across fluoroquinolones and beta-lactams, lowering surviving bacteria by roughly one log compared with antibiotic alone. These changes were reproduced in both mouse and human models and aligned with transcriptomic datasets linking lysosomal genes to innate immune pathways. The findings extend beyond the known immunomodulatory action of OM-89. Recurrent UTI guidelines have long noted intracellular bacterial reservoirs yet lacked host-directed adjuncts. By targeting epithelial degradation machinery, OM-89 addresses a mechanism that standard short-course antibiotics leave untouched, potentially reducing selection pressure for resistance. Prior observational cohorts showed 30-50 percent lower recurrence with OM-89 prophylaxis, but lacked cellular resolution; this study supplies a plausible mechanistic bridge. Next steps require randomized trials that pair OM-89 with first-line antibiotics and track both clinical recurrence and intracellular bacterial load via urine cytology or biopsy. Regulatory data from OM Pharma already support long-term safety, yet confirmation of additive efficacy in immunocompromised patients remains absent. If lysosomal potentiation holds in vivo, similar host-directed strategies could apply to other epithelial reservoirs such as gut or respiratory pathogens.